Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.49 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3482807 | 1.00 | LMNA (0.57) | LMNAADRB1ADRB3ADRB2SLC2A1 | |
| SCHEMBL3482675 | 1.00 | LMNA (0.57) | LMNAADRB1ADRB3ADRB2SLC2A1 | |
| Dimethylamine SCHEMBL27944752 | 0.94 | LMNA (0.52) | LMNAADRB1ADRB3ADRB2SLC2A1 | |
| SCHEMBL11595350 | 0.85 | LMNA (0.70) | LMNAADRB1ADRB3ADRB2AOC3 | |
| SCHEMBL13849942 | 0.85 | ADRB1 (0.48) | LMNAADRB1ADRB3ADRB2SLC2A1 | |
| SCHEMBL6690481 | 0.85 | ADRB1 (0.48) | LMNAADRB1ADRB3ADRB2SLC2A1 | |
| SCHEMBL13849930 | 0.85 | ADRB1 (0.48) | LMNAADRB1ADRB3ADRB2SLC2A1 | |
| SCHEMBL14402491 | 0.85 | ADRB1 (0.48) | LMNAADRB1ADRB3ADRB2SLC2A1 | |
| SCHEMBL1154749 | 0.83 | ADRB3 (0.49) | LMNAADRB1ADRB3ADRB2SLC2A1 | |
| SCHEMBL2879198 | 0.83 | ADRB3 (0.49) | LMNAADRB1ADRB3ADRB2SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119595791-A | Detection and analysis method for mutation-causing impurities in tomoxetine hydrochloride key starting material 3-chloropropanol | 植恩生物技术股份有限公司 | 2025-03-11 | — | — | CN | claimed |
| CN-112980895-B | Enzymatic synthesis method of (R) -3-chloropropanol | 宿迁阿尔法科技有限公司 | 2023-09-26 | — | — | CN | claimed |
| CN-112980895-A | Enzymatic synthesis method of (R) -3-chlorophenylpropanol | 宿迁阿尔法科技有限公司 | 2021-06-18 | — | — | CN | claimed |
| CN-112708641-A | Chemical-enzymatic synthesis method of tomoxetine | 上海医药工业研究院 | 2021-04-27 | — | — | CN | claimed |
| CN-108342418-A | A method of utilizing carbonyl reductase catalytic production (S) -3- chloro phenylpropanols | 浙江海洋大学 | 2018-07-31 | — | — | CN | claimed |
| WO-2012056229-A1 | INFLAMMATORY DISEASE | BIOCOPEA LIMITED (GB) | 2012-05-03 | — | — | WO | claimed |
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | PROTHENA BIOSCIENCES INC | 2025-03-27 | — | — | US | disclosed |
| CN-119595791-A | Detection and analysis method for mutation-causing impurities in tomoxetine hydrochloride key starting material 3-chloropropanol | 植恩生物技术股份有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-20240199612-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES (US) | 2024-06-20 | — | — | US | disclosed |
| CN-112980895-B | Enzymatic synthesis method of (R) -3-chloropropanol | 宿迁阿尔法科技有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-116589367-A | Preparation method of dapoxetine hydrochloride | 济南鸿湾生物技术有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-110937984-B | Dapoxetine hydrochloride related substance, preparation method and application thereof | 苏州科伦药物研究有限公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-113884611-A | Parradofovir mesylate related substance and application thereof | 西安新通药物研究股份有限公司 | 2022-01-04 | — | — | CN | disclosed |
| EP-0985649-A2 | Method for producing an aromatic compound having an alkyl group with at least three carbon atoms | TORAY INDUSTRIES, INC. (JP) | 2000-03-15 | — | — | EP | disclosed |
| WO-1997045115-A1 | PHARMACEUTICAL FOR TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | TROPHIX PHARMACEUTICALS, INC. (US) | 1997-12-04 | — | — | WO | disclosed |
| EP-0646047-A4 | ETCH-RESISTANT COATING. | BASF CORP (US) | 1995-05-17 | — | — | EP | disclosed |
| EP-0646047-A1 | ETCH-RESISTANT COATING | BASF CORPORATION (US) | 1995-04-05 | — | — | EP | disclosed |
| US-5281624-A | Neurological disorders associated with norepinephrine imbalance | ELI LILLY AND COMPANY (US) | 1994-01-25 | — | — | US | disclosed |
| WO-1992018255-A1 | ETCH-RESISTANT COATING | BASF CORPORATION (US) | 1992-10-29 | — | — | WO | disclosed |
| CN-1042704-A | FLUOXETINE ANALOG | LILLY CO ELI (US) | 1990-06-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250099442-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | DYRK2, DYRK1A, DYRK1B | LMNA 3414/4885ADRB1 2679/4885ADRB3 2743/4885 |
| US-20240199612-A1 | IMIDAZOPYRIDINYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK1, KLK4 | LMNA 1942/4885ADRB1 1937/4885ADRB3 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.